BIOCARDIA, INC.
OpenFilings analyst
Our analyst
Agentic read of the latest earnings call — recommendation updates when we process a new transcript. Research synthesis, not investment advice.
Speculative hold, not a buy:
BioCardia ended Q2 with $5.4 million of cash per the CFO, raised $4.9 million through its ATM at $1.22 per share, and expects runway into 2027, but remains dependent on further financing and regulatory execution. The Japan opportunity is potentially meaningful—an initial 20,000-patient indication and a competitor reimbursement benchmark of $326,000 per treatment—but PMDA still requires additional patient-level documentation, while U.S. HF2 enrollment is slow and patient totals were withheld.
- Japan Shonin
- Pmda Regulatory
- Cardiamp Hf2
- Helix De Novo
- Cash Runway
- Atm Financing
Near term
The key near-term catalyst is completion of the Japanese Shonin submission, targeted for Q4 2026; management identified CDISC data preparation, GCP audits, and responses to PMDA as remaining work.
HF2 enrollment could accelerate if additional capital supports site onboarding, but management acknowledged that enrollment is primarily driven by resources deployed and declined to disclose total enrollment.
The $4.9 million ATM financing improves liquidity but came at an average $1.22 per share, making continued equity funding a material dilution risk.
Longer term
Japan could become a substantial commercial opportunity if CardiAMP secures approval, reimbursement, and successful post-marketing adoption; management cites 300,000 ischemic heart-failure patients and 250,000 annual cardiac catheterization procedures, but these are market claims rather than revenue guidance.
The clinical efficacy signal is attractive, including an 82% average reduction in angina episodes and a 179-second improvement in exercise tolerance in BCDA-02, but the investment thesis still depends on confirmatory HF2 efficacy and regulatory acceptance.
Helix may have a data and experience advantage, with roughly 500 patients across more than a dozen trials, but a de novo approval would allow competitors to pursue 510(k) clearance referencing BioCardia's device.
A Japan approval could support expansion into Brazil, the UAE, and other markets, although management provided no commercial partner terms, launch economics, or geographic approval commitments.
Red flags
PMDA requested additional evidence that enrolled patients were on guideline-directed medical therapy and ineligible for revascularization, plus detailed reports for deaths, transplants, and LVAD implantation. Management believes the work is straightforward but has not quantified the regulatory risk or confirmed that Q4 submission timing is secure.
Management would not disclose the number of HF2 patients enrolled, acknowledged enrollment is not proceeding at a high pace, and said the primary outcome measure remains under discussion with FDA. The quality-of-life component has faced recent scientific criticism.
The FDA has not yet delivered formal Helix meeting minutes; management is relying on an email confirmation of its understanding. A de novo route could create a future 510(k)-based competitive pathway.
The $326,000 Japanese reimbursement level belongs to a different therapy and does not establish BioCardia's eventual price, reimbursement, market share, or profitability. Management's $6 billion implied opportunity was explicitly characterized by the analyst as potentially too high.
Liquidity remains fragile: Q2 operating cash use was $1.7 million, equity was only $2.7 million, and the company expects a financing-access benefit from a proposed SEC rule that is not yet implemented. The supplied takeaway also cites June 30 cash of $4.1 million, conflicting with the CFO's $5.4 million figure on the call.
OpenFilings analyst view from primary-source filings and earnings calls — not investment advice.
From latest 10-K · 2026-03-24
- Operating Cf Burn
- Net Margin Sharply Negative
- Cash Runway Low
- Accumulated Deficit High
Red flags
- Operating Cf Burn — Negative operating cash flow
- Net Margin Sharply Negative — Net margin -13700.0%
- Cash Runway Low — Cash runway ~0.3 years
- Accumulated Deficit High — Accumulated deficit / equity 18810%
Earnings transcripts
Press & signals
- GlobeNewswire
BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting
- GlobeNewswire
BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission
- GlobeNewswire
BioCardia Reports Second Quarter 2026 Business Highlights and Financial Results